A comprehensive custom panel design for routine hereditary cancer testing: preserving control, improving diagnostics and revealing a complex variation landscape by Castellanos, Elisabeth et al.
1Scientific RepoRts | 7:39348 | DOI: 10.1038/srep39348
www.nature.com/scientificreports
A comprehensive custom panel 
design for routine hereditary 
cancer testing: preserving 
control, improving diagnostics 
and revealing a complex variation 
landscape
Elisabeth Castellanos1,*, Bernat Gel1,*, Inma Rosas1, Eva Tornero2, Sheila Santín3, 
Raquel Pluvinet3, Juan Velasco3, Lauro Sumoy3, Jesús del Valle2, Manuel Perucho1, 
Ignacio Blanco4, Matilde Navarro2, Joan Brunet5, Marta Pineda2, Lidia Feliubadaló2, 
Gabi Capellá2, Conxi Lázaro2 & Eduard Serra1
We wanted to implement an NGS strategy to globally analyze hereditary cancer with diagnostic 
quality while retaining the same degree of understanding and control we had in pre-NGS strategies. 
To do this, we developed the I2HCP panel, a custom bait library covering 122 hereditary cancer genes. 
We improved bait design, tested different NGS platforms and created a clinically driven custom data 
analysis pipeline. The I2HCP panel was developed using a training set of hereditary colorectal cancer, 
hereditary breast and ovarian cancer and neurofibromatosis patients and reached an accuracy, 
analytical sensitivity and specificity greater than 99%, which was maintained in a validation set. I2HCP 
changed our diagnostic approach, involving clinicians and a genetic diagnostics team from panel design 
to reporting. The new strategy improved diagnostic sensitivity, solved uncertain clinical diagnoses and 
identified mutations in new genes. We assessed the genetic variation in the complete set of hereditary 
cancer genes, revealing a complex variation landscape that coexists with the disease-causing mutation. 
We developed, validated and implemented a custom NGS-based strategy for hereditary cancer 
diagnostics that improved our previous workflows. Additionally, the existence of a rich genetic variation 
in hereditary cancer genes favors the use of this panel to investigate their role in cancer risk.
Genetic diagnostic laboratories testing for cancer predisposition have rapidly integrated next-generation sequenc-
ing (NGS) technologies into their diagnostic workflows1–4. More genes have gradually been included to solve 
problems like genetic heterogeneity or overlapping clinical manifestations among distinct cancer predisposition 
syndromes5–10. Today, gene panels represent a good compromise between testing just a few genes and obtain-
ing information from the whole exome for routine hereditary cancer testing11–14. Comprehensive guidelines, 
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recommendations and standards have been published to guide the development, validation and implementation 
of NGS-based clinical genetic testing15–22. This material has aided the adaptation of NGS to the standardized 
frameworks developed for clinical genetic tests23. Despite these advances, for a genetic diagnostic laboratory 
mastering pre-NGS techniques, the biggest challenge when adopting NGS is to maintain the same degree of 
understanding and control over the whole process of detecting and interpreting genetic changes22,24.
The diagnostic activity of the ICO-IMPPC Joint Program for Hereditary Cancer focuses on the detection and 
interpretation of all inherited genetic variants that confer a higher risk of developing cancer. This activity encom-
passes all types of hereditary cancer (HC) syndromes, although we work mainly with hereditary colorectal cancer 
(Familial Adenomatous Polyposis, FAP, and Hereditary Non-Polyposis Colorectal Cancer, HNPCC), hereditary 
breast and ovarian cancer (HBOC) and neurofibromatoses Type 1 and Type 2 (NF1, NF2) and related disorders 
such as RASopathies and Phakomatoses. Due to genetic heterogeneity, clinical heterogeneity and overlapping 
clinical manifestations, diagnostic activity in the field of hereditary cancer requires multiple gene testing12,25,26.
To cover diagnostic necessities, homogenize diagnostic procedures for different conditions and preserve 
understanding and control over the complete workflow, we developed a comprehensive custom NGS-based diag-
nostic strategy to be implemented in the routine diagnostics scenario applicable to most of the genes involved in 
hereditary cancer and related disorders, similarly to other initiatives (Mainstreaming Cancer Genetics)27. Our 
aim was to develop a tool and a diagnostic strategy that would ensure the desired sequencing quality, provide 
great flexibility in the bioinformatic analysis to enhance clinical utility, and enable us to gather global data on the 
genetic variation of hereditary cancer.
Results
Development and validation of a hereditary cancer NGS panel. The I2HCP diagnostics NGS panel 
design and set up. We have developed the ICO-IMPPC Hereditary Cancer Panel (I2HCP), which comprises 122 
genes associated with cancer predisposition syndromes and RASopathies (Supplementary Table S1) and a custom 
data analysis pipeline. All genes had been previously identified as germline-mutated in relation to hereditary can-
cer (Cancer Census, OMIM or Orphanet). Combining all genes of interest in a single panel simplifies and unifies 
laboratory procedures in a single workflow when testing for the different conditions. The sequencing results are 
then filtered during the bioinformatic analysis and only selected genes are analyzed on the basis of the clinical 
indications (Fig. 1a).
To comply with the exhaustive analysis needed for diagnostics, the I2HCP regions of interest (ROIs) spanned 
all protein coding regions and intron-exon boundaries (− 35/+20 bp), including all regions usually left untar-
geted for technical reasons such as repeats and homologous regions. Sufficient coverage was sought to ensure 
that all bases within ROIs were covered at a minimum of 30x. In a first approach, a training set (n = 23, see 
Materials and Methods and Supplementary Table S2) was used to evaluate the performance of a first version of 
Figure 1. New genetic diagnostic workflow for hereditary cancer. (a) Detailed view of the ICO-IMPPC 
Hereditary Cancer Panel (I2HCP) including the three main steps: sample preparation, sequencing and data 
analysis. (b) The panel is part of the I2HCP diagnostic strategy, which also includes pre- and post-test clinical 
evaluation, optional additional analysis and evaluation of the pre-report by a multidisciplinary team.
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the SureSelect bait library, consisting of 106 genes that were sequenced in an Ion Torrent PGM sequencer using 
a 318 chip, pooling 4 samples before enrichment. Data were analyzed using both CLC Genomics Workbench 
(Qiagen) and our custom NGS pipeline (Fig. 2). This approach showed a good capture yield and a low percentage 
of non-covered regions: 1.54 × 106 ± 0.5 × 106 SD reads per sample were produced, the mean depth of coverage 
was 490.7 ± 221.5 SD, and more than 86% ± 4% SD of the targeted ROI bases was covered ≥ 30x. 123 out of 136 
pathogenic and non-pathogenic variants previously identified in the training set were correctly detected, pro-
viding a sensitivity of 90.4% (84.2–94.8%). However, this first approach failed to identify 7 out of 23 pathogenic 
variants, mostly due to their location within homopolymers (Supplementary Table S2).
On the basis of these initial results, two changes were made: a) To improve the percentage of well-covered 
regions, we studied coverage distribution and performed a systematic bait library redesign to increase the cover-
age of poorly covered regions (Supplementary Fig S1). In addition, we increased to 122 the number of genes in the 
panel (Supplementary Table S1); b) To improve variant calling quality, we analyzed all data using only our custom 
NGS pipeline, to ensure greater control over variant calling algorithms and parameters. We also decided to test 
the performance of a second sequencing platform: Illumina MiSeq.
Using the same training set of samples and the new bait library design, we set up a second approach based 
on the SureSelect XT protocol for Illumina, pooling 12 samples after enrichment and sequencing them in 
a Miseq 2 × 250 v2 cartridge (see Materials and Methods). Sequencing data were analyzed using our custom 
NGS pipeline (Fig. 2). 3.3 × 106 ± 0.83 × 106 SD paired reads were obtained per sample, the mean depth of 
coverage was 495 ± 170 SD and the coverage uniformity was of 0.31 ± 0.009 SD. More than 98.9% ± 0.7% SD 
of the targeted bases was covered ≥ 30× (Supplementary Fig S2). Detailed sequencing statistics are given in 
Supplementary Table S3. This new approach correctly identified 22 of the 23 pathogenic variants in the training 
set. The missing pathogenic mutation was located in the first exon of MSH6 gene and was not detected due to low 
coverage. As established in the I2HCP strategy (see implementation section), this exon was Sanger sequenced 
and the pathogenic variant identified (Supplementary Tables S2 and S4). In addition, all 113 previously iden-
tified non-pathogenic SNVs and indels were correctly detected (Supplementary Table S4). Taking into account 
all pathogenic and non-pathogenic variants previously identified in the training set, NGS data provided a sen-
sitivity of 100% (97.3–100%). We also detected 78 additional SNV in the ROIs of the genes previously tested 
by different methodologies (CSCE, cDNA sequencing, etc.). Most of these variants were known SNPs and all 
of them were either homozygous or located in intronic regions and thus not detected by pre-NGS analysis 
(Supplementary Table S4). Overall, no false positive was identified, resulting in a specificity of 100% (98.3–100%) 
for the training set.
Data analysis pipeline for NGS-based genetic diagnostics. NGS data were processed using a custom 
diagnostics-oriented data analysis pipeline, based on standard tools (BWA, VarScan2 and Annovar) and an 
extensive set of custom R scripts (see Material and Methods and Supplementary Figure S4). By creating a cus-
tom pipeline we were able to include several specific quality controls and measures such as targeted bases not 
reaching diagnostic quality, global and exon coverage measures, specific measures of variant quality for difficult 
regions, etc. We also ensured full control over the software used: the algorithms, the software versions and their 
specific parameters, which are locked for each version of the pipeline, and the data sources used for the basic 
First Approach
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design
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Figure 2. I2HCP set up and validation scheme. Summary of the different components of the two approaches 
developed. Training and validation sets are specified. The middle circle indicates improvements and changes 
made when designing the second approach.
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analysis (genome version, gene models… ) and annotations (dbSNP, ClinVar… ). All data were stored in a rela-
tional database and a custom pipeline management system was used to keep track of the analyses carried out. 
Finally, the full pipeline is under version control on our institution’s Git servers, enabling us to keep track of every 
modification and to revert to a previous version if necessary. In addition, in contrast to research-oriented NGS 
data analysis pipelines, our pipeline focuses on reducing false negatives at the expense of potentially increasing 
false positives, the latter of which would be uncovered in the Sanger variant validation step of the I2HCP strategy. 
Finally, we developed the first version of an exon-level copy-number calling algorithm based on successive steps 
of coverage depth normalization (see Material and methods). Although this is a preliminary version and not 
yet validated for diagnostics, it allowed us to correctly identify the true copy number changes in the training set 
(Supplementary Table S2) and therefore to increase the mutation detection yield.
Validation. After the I2HCP panel had been set up using the training set, an independent group of 40 sam-
ples was used as a validation set (Material and Methods; Fig. 2; Supplementary Table S5). These samples had 
previously been genetically characterized, with 36 found to have a known disease-causing mutation and 4 no 
pathogenic variant. We focused the variant analysis only on those genes tested in the previous genetic diagnostic 
workflows (Supplementary Table S1). The whole validation process was performed blindly. Each sample produced 
3.1 × 106 ± 0.58 × 106 SD paired reads, the mean depth of coverage was 398 ± 138 SD, the coverage uniformity was 
of 0.31 ± 0.02 SD, and 98.4% ± 1.0% SD of the targeted bases was covered ≥ 30× (Fig. 3; Supplementary Figure S2; 
Supplementary Table S3), similar to the performance achieved in the training set. This new approach correctly 
identified all 36 pathogenic variants in the validation set, including substitutions, small insertions/deletions (up 
to 19 bp), and deletions of a single exon and a whole gene. No pathogenic variants were identified in the 4 samples 
that previously tested negative (see Supplementary Table S5). In addition, 180 out of 186 previously identified 
variants were detected (VUS and polymorphisms). Of the 6 missing variants, one was located in a low-coverage 
region of the MSH6 gene, and the remaining 5 in a highly complex region of PMS2. These regions are routinely 
re-analyzed by Sanger sequencing (see Implementation section; Supplementary Figure S3). Therefore, consider-
ing the 358 known variants in the training and validation sets, the analytical sensitivity of the panel was 98.4% 
(96.4–99.4%) and the analytical specificity was of 100% (99–100%). In addition, considering the whole set of 122 
genes, within-run precision (repeatability) was 98% (97–98.7%) and between-run precision (reproducibility) was 
95.7% (94.6–96.6%), both within the optimal range for diagnostic purposes (ref. 19; see Material and Methods 
for details).
Implementation into routine genetic testing: an I2HCP-based diagnostic strategy. Once the 
I2HCP had been validated, we modified the overall HC diagnostic strategy to unlock the potential of the new 
panel and integrated it into routine genetic testing (Fig. 1b). As in pre-NGS diagnostics, the clinical presentation 
of patients drives the diagnostic approach, thus a pre-test clinical evaluation of the hereditary cancer condition 
in question is required before initiating genetic testing. Next, sample preparation, NGS sequencing and data 
c.a.
b.
Figure 3. Coverage Analysis. Analysis of the depth of coverage of the samples in the validation set. (a) The 
percentage of bases of the ROIs above a given coverage level. The red vertical line corresponds to C30 (98.4%). 
(b) The relationship between GC content and depth of coverage. Each dot represents a single exon. GC content 
was computed as the percentage of G/C in the exon sequence. The coverage was computed as the mean coverage 
of the exon over all samples in the validation set. (c) Density plot showing the coverage distribution along all 
ROIs over all samples in the validation set. The exon is represented as a black box and intron/exon boundaries 
as grey lines. The exonic coverage was computed as the mean over 200 equally sized windows to normalize the 
exon length. Intronic coverage is plotted as one position per base. The blue background represents the density of 
exons with a given coverage at a given position. The yellow line represents the mean coverage, the dashed orange 
lines represent the Q1 and Q3 quartiles and the dotted orange lines the 5 and 95 percentiles. Finally, the purple 
horizontal line represents the mean coverage and the red line the minimum coverage threshold of 30x.
www.nature.com/scientificreports/
5Scientific RepoRts | 7:39348 | DOI: 10.1038/srep39348
analysis are performed for the whole set of 122 genes; only genes with current clinical utility for each hereditary 
cancer condition are then further analyzed up to variant interpretation. The groups of genes with clinical utility 
for HBOC, FAP, HNPCC and neurofibromatosis have been pre-defined by clinicians and the genetic diagnostics 
team (Supplementary Table S1). The panel format provides the flexibility to select ad hoc groups of genes for 
other conditions or particular clinical presentations or to broaden the test, even after a first round of analysis. 
Any ROI of the analyzed gene set with a single base below 30x coverage is Sanger sequenced to ensure diag-
nostic quality. The total number of Sanger sequencing required is low and the regions involved are recurrent 
(Supplementary Table S6 and Figure S3). We also use Sanger sequencing as an independent technique to validate 
all reportable variants.
Since the I2HCP diagnostic strategy was implemented into our laboratory routine, more than 150 sam-
ples have been processed. In general, quality parameters have improved with respect to the validation set 
(3.2 × 106 ± 1.5 × 106 SD paired reads; mean depth 452 ± 225 SD; uniformity 0.31 ± 0.02 SD; C30 99.2 ± 0.7 SD). 
At the same time, the custom development of I2HCP has provided the plasticity required for continuous devel-
opment and rapid updates. Since its implementation in routine diagnostics, the sequencing kit has changed from 
v2 (2 × 250 cycles) to v3 (2 × 300 cycles), the number of genes has increased to 126 (including the genes LZTR1, 
PIK3CA, RASA2 and GRB2), the number of samples per MiSeq run has increased from 12 to 16, and multiple 
upgrades in variant annotation have been made.
Despite the excellent analytical sensitivity and specificity it provides, the I2HCP NGS panel does not consist-
ently detect some types of pathogenic variants present in the mutational spectrum of these genes and syndromes 
(e.g., deep intronic mutations, insertion of repetitive elements, etc.). Thus, other techniques such as mRNA anal-
ysis could be integrated to complement the I2HCP in particular cases. In addition, for some conditions, consti-
tutional copy-number alterations (CNA) account for a considerable percentage of disease-causing mutations. A 
clear example is neurofibromatosis type 1, in which about 7% of mutations in the NF1 gene are due to total gene 
deletions or intragenic CNAs28. Analysis of the CNAs of specific genes is part of the I2HCP diagnostic strategy 
and is mainly carried out by MLPA, depending on the condition and clinical status of each patient. Although the 
I2HCP is not yet validated for routine genetic diagnostics, it can be used for CNA analysis. Since the I2HCP strat-
egy was introduced, 100 samples have been complemented by MLPA analysis of different genes (171 MLPA tests). 
We have also analyzed the presence of CNAs in these 100 cases by applying an exon-level copy-number calling 
algorithm as part of the I2HCP pipeline. Ninety-nine samples have been analyzed (1 sample, corresponding to 3 
MLPA analyses, did not reach the minimum quality criteria for analysis). Of the remaining 168 CNAs analyses, 
159 were negative and 9 positive (8 whole gene deletions and one two-exon deletion). In all cases, MLPA and 
I2HCP results were concordant (Supplementary Table S7).
The overall analysis, including genetic variant interpretation and complementary tests, is summarized in a 
pre-report that is evaluated by a multidisciplinary team. Depending on the results and the patient’s clinical pres-
entation, clinicians may request the analysis of additional genes in the I2HCP panel. Since NGS data are already 
available and processed, the analysis can start at the gene-filtering step of the pipeline. Finally, a report compliant 
with EuroGentest recommendations is generated and clinicians perform a post-test clinical evaluation concern-
ing genetic counseling and clinical management.
The new genetic testing strategy improves HC diagnostics. One of the questions raised by the enhanced test-
ing potential of the I2HCP-based strategy is whether retrospective re-analysis is warranted for particular cases 
that tested negative in previous diagnostic workflows or for uncertain clinical presentations that did not fully 
meet testing criteria. As a pilot study, we selected a group of 14 cases for re-analysis with the new strategy 
(Material and methods; Table 1). This group comprised 2 HBOC, 10 HNPCC positive for the Amsterdam cri-
teria, 1 Schwannomatosis and 1 patient with clinical suspicion of NF1. In all cases, in addition to the respective 
clinically-driven gene lists (Supplementary Figure S1), we analyzed all 122 genes in the I2HCP. As seen in Table 1, 
the re-analysis enabled us to solve one case with an uncertain clinical diagnosis: a whole CDKN2A deletion caus-
ing melanoma and neural system tumor syndrome (OMIM: 155755) was identified in the patient with clinical 
suspicion of NF1 (Sample R2) (Supplementary Figure S5). The re-analysis also allowed us to increase the sen-
sitivity of mutation detection by analyzing the pre-defined sets of genes (e.g.: Samples R1 and R4). Finally, the 
analysis of the whole I2HCP identified variants in new genes with potential impact on the clinical phenotype (e.g., 
samples R3, R5 and R6).
Variation landscape of hereditary cancer genes in hereditary cancer patients. I2HCP contains 
the majority of genes currently associated with hereditary cancer. The creation of a comprehensive panel was 
intended primarily to facilitate diagnostic activity, but it was also designed to facilitate the compilation of all 
genetic variants present in genes associated with cancer predisposition. Thus, it was possible to generate a global 
view of the constitutional variation present in these genes from the raw data produced for genetic testing. This 
opens the possibility of studying not only the disease-causing mutation but also the contribution of this variation 
to the presentation and evolution of the disease. Figure 4 shows the variation landscape of the genes in I2HCP 
for the 63 individuals in the training and validation sets. In particular, it contains the variants present in coding 
regions and canonical splice sites with a minor allele frequency (MAF) below 1%.
The global analysis revealed a complex variation landscape that coexists with the disease-causing mutation, 
including nonsense, frameshift, splicing, missense and synonymous variants. The number of variants per indi-
vidual ranges from 1 to 9, with an average of 5, and presents no differences among HC conditions. Similarly, not 
taking into account the disease-causing mutation, there is diversity in the number of variants per gene, with the 
top 10% of genes accounting for around 40% of the genetic variation. In 27 cases a patient had more than one 
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6Scientific RepoRts | 7:39348 | DOI: 10.1038/srep39348
Sample 
Cancer history (proband 
and 1st and 2nd degree 
relatives) Clinical criteria Previous analysis
I2HCP 
analysis Coding non-synonymous infrequent detected variants
Functional 
prediction
Sample_R1
Proband: endometrial 
c (59y). Mother: breast 
c (41y), colon c (42y). 
Maternal aunt: endometrial 
c (45y). Maternal uncle: 
Gastric (57)
HNPCC, 
Amsterdam 
Criteria
Conserved MLH1/
MSH2 and non-
evaluable MSH6 
expression in 
proband’s tumor. 
MSH6 genetic 
analysis negative
1) Lynch 
genes set
MSH2:NM_000251:exon3:c.G437T:p.G146V Neutral
MSH6:NM_000179:exon9:c.3952_3960del:p.1318_1320del Deleterious
2) Whole 
I2HCP
EPCAM:NM_002354:exon3:c.G267C:p.Q89H Deleterious
APC:NM_001127510:exon11:c.G1139A:p.R380Q Deleterious
PMS2:NM_000535:exon11:c.C1169T:p.A390V Neutral
FANCC:NM_000136:exon2:c.C77T:p.S26F Deleterious
SDHD:NM_003002:exon1:c.G34A:p.G12S Neutral (ClinVar:PAT)
FANCM:NM_020937:exon20:c.C4799T:p.T1600I Deleterious
BRCA1:NM_007294:exon10:c.G3119A:p.S1040N Neutral
BBRCA1:NM_007294:exon10:c.C2521T:p.R841W Deleterious
MN1:NM_002430:exon1:c.G56A:p.G19D Deleterious
Sample_R2
Proband: Malignant 
fibrous histiocytoma 
(an undifferentiated 
pleomorphic sarcoma), a 
glioblastoma multiforme 
and 3 neurofibromas
NF1 None
1) NF1 genes 
set No candidate variant detected
2) Whole 
I2HCP
Whole CDKN2A gene deletion. Validated by MLPA Deleterious OMIM: 155755
ATM:NM_000051:exon50:c.C7375G:p.R2459G Neutral
Sample_R3 
(V11)
Proband: breast c (46y), 
skin c (49y), uterine 
c (60y), skin c (60y), 
thyroidectomy due to 
multinodular hyperplasia 
(45y). Father: gastric c 
(55y). Sister: ovarian c 
(Brenner t., 39y). Sister’s 
son: breast c (34y, BRCA2 
VUS c.5729A> T carrier).
HBOC BRCA1/2 genetic analysis negative
1) HBOC 
genes set No candidate variant detected
2) Whole 
I2HCP
FANCL:NM_001114636:exon14:c.1111_1114dupATTA:p.
Thr372Asnfs* Deleterious
BARD1:NM_000465:exon11:c.C2191T:p.R731C Deleterious
CHEK2:NM_007194:exon14:c.C1525T:p.P509S Neutral
PMS2:NM_000535:c.1866G> A:p.M622I Insight: Class 1
Sample_R4 
(V30)
Proband: breast c (46y). 
Mother: breast c (77y).
Maternal aunt: ovarian c 
(58y). Maternal uncle: CCR 
(67y). Paternal aunt-1: 
ovarian c (56y). Paternal 
aunt-2: ovarian c ? Paternal 
uncle: CCR ?
HBOC BRCA1/2 genetic analysis negative
1) HBOC 
genes set
PALB2:NM_024675:exon9:c.G2993A:p.G998E Deleterious
PALB2:NM_024675:exon5:c.G2014C:p.E672Q Neutral
2) Whole 
I2HCP SUFU:NM_016169:exon7:c.G856A:p.E286K Neutral
Sample_R5
Proband: 2 breast c (62, 
69y), endometrial c (77y). 
Son: prostate c (64y). 
Mother: breast c (75y). 
Father: colon c (52y). Sister: 
colon c (49y). Brother: 
prostate c (74y).
HNPCC, 
Amsterdam 
Criteria
MSH2 and MSH6 
LoE in proband’s 
endometrial tumor. 
MSH2 & MLH1 
genetic analysis 
negative
1) Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP
PPM1D:NM_003620:exon6:c.1736_1737insA:p.T579fs Deleterious
XPC:NM_004628:exon2:c.C142T:p.L48F Neutral
WRN:NM_000553:exon9:c.G1149T:p.L383F Neutral
WRN:NM_000553:exon25:c.G2983A:p.A995T Neutral
MLH3:NM_014381:exon2:c.G1870C:p.E624Q Deleterious
PALB2:NM_024675:exon5:c.C2135T:p.A712V Neutral
Sample_R6
Proband: colon c (43y). 
Mother: colon c (73y). 
Maternal uncle-1: colon c 
(22y). Maternal uncle-2: 
colon c (41y). Maternal 
aunt: colon c (73y)
HNPCC, 
Amsterdam 
Criteria
Microsatellite 
stability in proband’s 
tumor. MSH2 & 
MLH1 genetic 
analysis negative
1) 3 Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP
BMPR1A:NM_004329:exon4:c.A223G:p.T75A Deleterious
FH:NM_000143:exon7:c.C926T:p.P309L Deleterious
RAD50:NM_005732:exon16:c.C2548T:p.R850C Deleterious
ATM:NM_000051:exon37:c.A5558T:p.D1853V Deleterious
SLX4:NM_032444:exon15:c.A5501G:p.N1834S Neutral
Sample_R7 
(V21)
Proband: colon c (39y). 
Mother: gastric c (61y). 
Maternal grandfather: skin 
c (60y).
HNPCC, Bethesda 
criteria
Microsatellite 
instability and MLH1 
LoE in proband’s 
tumor. MLH1 genetic 
analysis negative
1) Lynch 
genes set APC:NM_000038:exon16:c.T3920A:p.I1307K Neutral
2) Whole 
I2HCP
ERCC6:NM_000124:exon10:c.C1996T:p.R666C Deleterious
ERCC6:NM_000124:exon18:c.A3122C:p.Q1041P Neutral
DDB2:NM_000107:exon9:c.G1228A:p.A410T Neutral
ATM:NM_000051:exon41:c.A6084T:p.Q2028H Neutral
FANCM:NM_020937:exon21:c.A5627G:p.N1876S Neutral
EXO1:NM_003686:exon10:c.G1378C:p.V460L Neutral
Sample_R8
Proband: Biliary tract c 
(43y). Father: colon c (52y). 
Brother: colon c (42y). 
Sister: breast c (55y)
HNPCC, 
Amsterdam 
Criteria
MSI-H and MLH1 
LoE in proband’s 
tumor. MLH1 genetic 
analysis negative
1) Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP ERCC4:NM_005236:c.2624A> G:p.E875G Deleterious
Continued
Sample 
Cancer history (proband 
and 1st and 2nd degree 
relatives) Clinical criteria Previous analysis
I2HCP 
analysis Coding non-synonymous infrequent detected variants
Functional 
prediction
Sample_R9
Proband: colon c (59y), 
lung c (67y). Father: 
colon c (68y). Sister: 
colon c (45y). Sister’s son: 
leukaemia (25y). Brother: 
colon c 63(y)
HNPCC, 
Amsterdam 
Criteria
MLH1 LoE in 
proband’s tumor. 
Absence of MLH1 
somatic methylation. 
MLH1 genetic 
analysis negative
1) Lynch 
genes set PMS2:NM_000535:c.1866G> A:p.M622I Insight: Class 1
2) Whole 
I2HCP
PRSS1:NM_002769:exon5:c.G617C:p.C206S Deleterious
PALB2:NM_024675:exon9:c.G2993A:p.G998E Deleterious
Sample_R10
Proband: colon c (31y). 
Father: 3 colon c (67, 67 
and 68y). Paternal aunt: 
endometrial c (50y)
HNPCC, 
Amsterdam 
Criteria
MLH1 LoE in 
proband’s tumor. 
Absence of MLH1 
somatic methylation. 
MSH2 & MLH1 
genetic analysis 
negative
1) Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP
EXO1:NM_130398:c.1918C> G:p.P640A Neutral
PTPN11:NM_002834:exon14:c.C1658T:p.T553M Neutral
FANCA:NM_000135:exon27:c.C2574G:p.S858R Neutral
FLCN:NM_144997:exon9:c.G979A:p.A327T Neutral
MN1:NM_002430:exon1:c.G3550C:p.E1184Q Deleterious
Sample_R11
Proband: colon c (58y). 
Mother: colon c (70y). 
Brother: colon c (47y)
HNPCC, 
Amsterdam 
Criteria
MSH6 LoE in 
proband’s tumor. 
MSH2 & MSH6 
genetic analysis 
negative
1) Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP
BARD1:NM_000465:exon7:c.G1670C:p.C557S Neutral
MRE11A:NM_005590:exon13:c.C1475A:p.A492D Deleterious
SLX4:NM_032444:exon15:c.A5501G:p.N1834S Neutral
BRCA1:NM_007294:exon10:c.G3119A:p.S1040N Deleterious
Sample_R12
Proband: ovary c (35y). 
Mother: endometrial c 
(79y). Maternal uncle 1: 
colon c (63y). Maternal 
uncle 2: prostate c (79y)
HNPCC, 
Amsterdam 
Criteria
MSH2/MSH6 LoE 
in proband’s tumor. 
MLH1, MSH2 
& MSH6 genetic 
analysis negative
1) Lynch 
genes set No candidate variant detected
2) Whole 
I2HCP
EXO1:NM_130398:c.2276G> A:p.G759E Neutral
HNF1A:NM_000545:exon4:c.C827G:p.A276G Deleterious
BRCA2:NM_000059:exon11:c.G4258T:p.D1420Y Neutral
PALB2:NM_024675:exon7:c.C2590T:p.P864S Neutral
PALB2:NM_024675:exon4:c.G232A:p.V78I Neutral
PRKAR1A:NM_002734:exon3:c.G221A:p.R74H Deleterious
Sample_R13
Proband: colon c (37y). 
Father: colon c (57y). 
Grandfather: colon c (60y)
HNPCC, 
Amsterdam 
Criteria
MSH6 LoE in 
proband’s tumor. 
MLH1, MSH2 
& MSH6 genetic 
analysis negative
1) Lynch 
genes set POLE:NM_006231:exon42:c.A5797G:p.I1933V Neutral
2) Whole 
I2HCP
FANCD2:NM_001018115:exon28:c.G2702T:p.G901V Neutral
ATM:NM_000051:exon22:c.C3161G:p.P1054R Deleterious
PALB2:NM_024675:exon7:c.C2590T:p.P864S Neutral
Sample_R14 
(V39)
Proband: Multiples 
schwannomas Schwannomatosis
NF2 and SMARCB1 
genetic analysis 
negative
1) NF2 genes 
set No candidate variant detected
2) Whole 
I2HCP
BARD1:NM_000465:exon11:c.A2146G:p.T716A Neutral
ERCC6:NM_000124:exon16:c.G2924A:p.R975Q Deleterious
SUFU:NM_016169:exon8:c.G1018T:p.A340S Neutral
ATM:NM_000051:exon17:c.T2572C:p.F858L Neutral
ATM:NM_000051:exon22:c.C3161G:p.P1054R Deleterious
FANCA:NM_000135:exon42:c.C4249G:p.H1417D Deleterious
FANCA:NM_000135:exon27:c.T2507A:p.F836Y Neutral
Table 1.  Sample re-analysis pilot study. Results of the re-analysis of 14 samples, including 4 samples from the 
validation set (V11, V30, V21 and V39). The I2HCP analysis encompasses the rare exonic non-synonymous 
variants detected in: 1) the genes included in the predefined gene group on the basis of clinical manifestations 
(Supplementary Table S1) and 2) the variants found in all genes of the panel. 1000G frequencies <0.01% have 
been used to filter rare variants. Variants highlighted in bold could be responsible for the developed phenotype. 
Further analyses are needed to evaluate the impact of these variants. Functional prediction is based on data 
from Polyphen2 HDIV and HVAR, SIFT, PROVEAN and MutationTaster and a variant is marked as deleterious 
if three or more predictors classified it as damaging.
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variant in the same gene, accounting for 55 out of 278 variants present. In 8 of the 27 cases these multiple variants 
accumulated in the disease-causing gene (data not shown).
Although this variation landscape represents only a small number of HC patients, some notable observations 
can be made. For instance, although tuberous sclerosis patients were not considered in this study, the TSC2 gene 
was among the genes that accumulated more variation, most of which had a very low MAF. Additionally, most 
nonsense, frameshift and splicing variants concentrate in DNA repair genes. Finally, there are a number of poten-
tially pathogenic variants in genes not directly related to the phenotype that could be worth exploring. It would 
therefore be interesting to study the complexity of this variation landscape and its relationship with the presented 
cancer phenotypes in a larger sample.
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Discussion
The adoption of NGS technology by a routine genetic diagnostics laboratory presents various challenges29, among 
them the new competences required for both wet and dry labs and the complete reorganization of diagnostic 
activity. However, crucial to genetic testing is the ability to maintain understanding and control over the whole 
diagnostic workflow, to identify the potential limitations in the detection and interpretation of genetic variants 
and the implications for the diagnostic report. The prospective integration of new NGS methodologies and more 
complex bioinformatic analysis raised concerns about possible loss of overall control, so we decided to custom-
ize our NGS diagnostic strategy as far as possible. This was achieved by developing an NGS-based workflow 
comprising a panel of 122 HC genes and a clinically driven custom data analysis pipeline. We designed ROIs to 
comprehensively sequence all coding exons and desired intron-exon boundaries of hereditary cancer genes and 
RASopathies according to our diagnostic activity. The custom nature of I2HCP provides the plasticity for contin-
uous and rapid updating. In the few months since the I2HCP strategy was implemented for routine diagnostics, 
the number of genes in the panel has increased, sequencing procedures and pipeline analysis have been updated 
and more samples per run can be tested.
According to Eurogentest NGS recommendations18 I2HCP can be considered a Type A test, given the high 
sensitivity and specificity achieved during the development and validation processes. However, it must be taken 
into account that the panel was set up by analyzing HBOC, FAP, HNPCC and neurofibromatosis patients. 
Although the quality parameters apply to all genes tested, for genes and conditions with particular mutational 
spectrums or testing complexities a specific analysis of I2HCP performance could be required.
The custom panel provides great flexibility, allowing for the analysis of pre-established gene sets for particular 
clinical conditions but also the testing of specific genes on demand (up to the entire set of 122 genes) in those 
cases with distinct clinical presentations. The customization of the panel and its comprehensive nature foster 
interplay and dialog between clinicians and the genetic diagnostics team for panel design, evaluation of results, 
the possible need to analyze additional genes, and reporting. In addition, the results of the re-analysis pilot study 
show the potential of applying the new strategy to previous negative tests and to patients who do not fully meet 
clinical criteria.
The I2HCP diagnostic strategy compensates for the limitations of the panel by integrating Sanger sequencing 
of complex and low-coverage regions, mRNA analysis when required and CNA analysis by MLPA. The I2HCP 
CNA detection algorithm has shown a 100% concordance with MLPA results in the 168 assessable tests per-
formed so far. Robust development of this algorithm could substantially reduce the number of MLPAs required 
for diagnostics.
The global analysis of all genes in the panel revealed a complex variation landscape that coexists with the 
known disease-causing mutation. The number of variants identified per individual and the frequency of variants 
per gene were consistent with previous reports using other panels11. The study of this global variation and the 
systematic collection of genetic and phenotypic data in a higher number of patients could provide the evidence 
needed to establish additional genes as conferring cancer predisposition and to make reliable risk estimates for 
patient management and counseling30–32.
Conclusions
In summary, we developed and validated a custom NGS-based diagnostic strategy for hereditary cancer and 
implemented it into our routine diagnostic activity. The mutation detection rate increased, while maintaining 
control over the whole process. Complete analysis of the 122 hereditary cancer genes tested revealed a complex 
variation landscape that coexists with the disease-causing mutation. Analysis of this landscape in a higher num-
ber of patients could help to better estimate individual cancer risk.
Methods
Subjects. This study was approved by the IMPPC scientific direction and carried out in accordance with 
IMPPC guidelines. Signed informed consent was obtained from all participants. Genomic DNA from 73 unre-
lated individuals clinically diagnosed with a cancer predisposition syndrome was obtained from blood lympho-
cytes using standard protocols. The 73 samples were grouped in three different sample sets: training, validation 
and re-analysis. The training set comprised 23 samples from patients who met the clinical criteria for HBOC 
(n = 7), FAP (n = 2), HNPCC (n = 7), NF1 (n = 6) and NF2 (n = 1). The validation set comprised 13 HBOC 
patients, 7 FAP, 11 HNPCC, 5 NF1, 2 NF2 and 1 patient who met the clinical criteria for Schwannomatosis, for 
a total of 40 samples. These samples contained 222 variants (36 pathogenic plus 186 VUS and polymorphisms), 
which was sufficient to determine specificity and sensitivity with a 95% CI of width < 1.3%23. All samples had 
been genetically tested using pre-NGS workflows and methods (cDNA and DNA Sanger sequencing, conforma-
tion-sensitive capillary electrophoresis (CSCE), denaturing high-performance liquid chromatography (DHPLC) 
and multiplex ligation-dependent probe amplification (MLPA)). These samples presented a broad mutational 
spectrum, including single-nucleotide variants (SNVs), small insertions and deletions and multiple exon dele-
tions, many of them located in complex sequence contexts (Supplementary Figure S6). Finally, the re-analysis 
set consisted of 14 individuals: 9 HNPCC positive for the Amsterdam criteria, 1 NF1 and 4 patients from the 
validation set with no pathogenic mutation as detected by pre-NGS testing workflows (Supplementary Table S1). 
Moreover, the global results for the 150 patients genetically diagnosed using I2HCP were compared to the train-
ing and validation sets. The testing criteria for these patients were based on current international clinical criteria 
guidelines33. Samples were codified and mutation analysis was performed blindly for the validation set.
Enrichment. We used Agilent eArray to design our SureSelect bait library V1 (Agilent, California, USA), 
covering 106 genes for a total of 0.45 Mb. For each gene, we defined the ROIs as all coding exons and intron/
exon boundaries (− 35/+20 bp) of all translated isoforms according to NCBI human genome build 37 (GRCh37) 
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Figure 4. Variation landscape of hereditary cancer genes. Matrix representation of the rare variants found 
in the training and validation samples. Only variants with a MAF below 1% in all populations from 1000 
Genomes or ExAc projects are included. Each row represents a gene and each column a sample. Samples are 
ordered by clinical condition and by total number of variants. Genes are ordered by total number of variants 
without taking into account the disease-causing mutation. Each cell of the matrix is colored according to the 
type of variant found: red for nonsense, orange for frameshift, purple for splicing, blue for missense, yellow 
for synonymous and green for copy-number variants. If more than one variant was found in a given gene on a 
given sample, the color of the most damaging variant was used. Missense variants were further separated into 
two groups according to in-silico functional impact predictions using data from Polyphen2 HDIV and HVAR, 
SIFT, PROVEAN and MutationTaster. If more than 3 of the algorithms classified the variant as neutral, it was 
considered a neutral variant and colored in light blue; otherwise it was considered a possibly damaging variant 
and colored with dark blue. Bars on the right hand side represent the total number of variants per gene and their 
type. The bottom bars represent the total number of variants per sample. Finally, black diamonds denote the 
disease-causing mutations.
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and the Ensembl release 67. All ROIs were exhaustively covered with capture baits. A second design was devel-
oped after studying the behavior of V1 baits to improve capture results. In short, we monitored the coverage 
of all exons, identified problematic regions, performed a systematic rebalancing of baits and increased bait til-
ing using custom algorithms to improve capture of poorly covered areas and to enhance coverage uniformity 
(Supplementary Figure S1). The bait library V2 included 122 genes responsible for most of the cancer predisposi-
tion syndromes and RASopathies (Supplementary Table S1), for a total of 0.5 Mb of targeted DNA.
Sample preparation and sequencing. DNA was sonicated using a Covaris S2 (Covaris, Woburn, MA, 
USA). Sample preparation was performed following the SureSelect XT protocol for Ion Torrent or MiSeq. In 
the first approach, samples were enriched with bait library V1 after combining 4 equimolar indexed samples 
(pre-capture pooling) and sequenced in a PGM (Ion Torrent) 318 chip with One Touch 200 DLv2 template rea-
gents and Ion PGM 200 sequencing reagents. In the second approach, 12 samples were enriched with bait library 
V2 according to the manufacturer’s instructions (Agilent) with minor modifications34, pooled after capture and 
sequenced in a MiSeq (Illumina) with Reagent Kit v2, 2 × 250.
Validation by Sanger Sequencing. For the subset of genes analyzed for a patient, any ROI with at least one 
base below 30x was Sanger sequenced using standard protocols (primer sequences available upon request). 30x 
minimum coverage was established as per De Leener et al.35. Reportable variants (all pathogenic variants and VUS 
only for some syndromes) were also validated by Sanger sequencing. Human Genome Variation Society (www.hgvs.
org) nomenclature guidelines were used to name the mutation at the DNA level and the predicted resulting protein.
Bioinformatic Analysis. NGS data were processed using a custom data analysis pipeline based on standard 
tools. In short, fastq files were mapped against the GRCh37 human genome assembly corresponding to Ensembl 
release 6736 using BWA mem37 and a sorted bam file was created with samtools38. Exhaustive coverage metrics 
were produced using a combination of bedtools39 and custom R and Bioconductor40 scripts. Variants, including 
substitutions and small insertions and deletions, were called using VarScan241 with the following parameters: 
–min-coverage 10 –min-reads2 2 –min-avg-qual 15 –min-var-freq 0.1 –strand-filter 0. Finally, variants were 
annotated with a combination of annovar42 and custom scripts. bam-readcount was then used to compute addi-
tional quality parameters (quality of the bases supporting the reference and alternative alleles, position of the 
changes in the reads, number of mismatches present in reads supporting the alternative allele, etc.) that were 
combined to produce a set of variant quality indicators to guide the variant validation process. Final variant 
annotation included: basic variant quality parameters, gene and transcript annotations and effects, presence in 
variation databases (dbSNP and ClinVar), population frequencies (1000 G, ExAC and ESP6500) and in-silico pre-
diction of effects in protein function (Polyphen2, SIFT, MutationAssessor, MutationTaster, PROVEAN, CADD). 
All information, including coverage metrics, variants, variant quality estimators and annotations, was stored in a 
PostgreSQL database. Variants were filtered using the regioneR bioconductor package43 according to the clinical 
indication prior to generating the variant lists. The preliminary algorithm for exon-level copy-number estimation 
includes different normalization steps on the exon mean depth of coverage (including mean sample coverage 
and mean exon coverage across samples), similar to Kang et al.44, and was run using a set of custom scripts. 
CLC Genomics Workbench v6 (Qiagen) was used to analyze data from I2HCP V1. Repeatability was measured 
by comparing the variants called for four samples prepared and sequenced twice under the same conditions. 
Reproducibility was calculated for twelve samples prepared once and sequenced twice in independent runs. In 
both cases, the concordance was computed as the number of common variants divided by the total number of 
variants identified. 95% confidence intervals were computed using the exact method from Hmisc R package. 
Uniformity was defined as the percentage of bases with a coverage within ± 20% of the mean coverage. C30 was 
defined as the percentage of ROI bases with coverage ≥ 30x.
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